Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	$ (2,515,106)	$ (8,041,372)
Adjustments to reconcile net loss to net cash provided by/(used in) operating activities
Depreciation	338,682	368,102
Loss on disposal of property and equipment	0	1,213
Stock-based compensation expense	1,270,203	776,994
Stock issued for services	106,874	135,000
Write off of deferred financing costs	67,664	86,736
Amortization of debt discount	155,996	218,394
Loss on deconsolidation of biologistex	0	2,785,910
Loss from equity-method investment in SAVSU	1,004,880	0
Amortization of deferred rent related to lease incentives	(126,998)	(126,997)
Accretion and amortization on available for sale investments	0	1,792
(Increase) Decrease in
Accounts receivable, trade	172,331	(264,357)
Inventories	(88,962)	(290,838)
Prepaid expenses and other current assets	(180,663)	73,255
Increase (Decrease) in
Accounts payable	20,580	233,482
Accrued compensation and other current liabilities	293,743	(410,151)
Accrued interest	152,143	97,857
Deferred rent	(66,245)	27,989
Net cash provided by/(used in) operating activities	605,122	(4,326,991)
Cash flows from investing activities
Sales/maturities of available-for-sale investments	0	1,650,000
Costs associated with internal use software development	0	(1,113,675)
Purchase of property and equipment	(143,767)	(143,533)
Net cash provided by/(used in) investing activities	(143,767)	392,792
Cash flows from financing activities
Proceeds from note payable to related party	1,000,000	3,000,000
Proceeds from exercise of common stock options and warrants	3,978,336	278,503
Payments on equipment loan	(13,081)	0
Payments on capital lease obligation	(10,901)	0
Payments related to preferred stock issuance	(9,303)	0
Payments of preferred stock dividends	(106,250)	0
Deferred costs paid related to potential stock issuance	(42,664)	(111,736)
Net cash provided by financing activities	4,796,137	3,166,767
Net increase/(decrease) in cash and cash equivalents	5,257,492	(767,432)
Cash and cash equivalents - beginning of year	1,405,826	2,173,258
Cash and cash equivalents - end of year	6,663,318	1,405,826
Non-cash investing and financing activities
Stock issued for services in prior period included in liabilities at year-end	35,624	0
Capital lease obligations incurred for purchase of equipment	52,327	0
Purchase of equipment with debt	39,243	0
Debt discount related to warrants	0	374,390
Deferred costs related to potential stock issuances not yet paid	0	26,975
Purchase of property and equipment not yet paid	22,003	0
Series A Preferred Stock [Member]
Non-cash investing and financing activities
Series A preferred stock dividends accrued not yet paid	106,250	0
Preferred stock issued to convert related party note payable and accrued interest	$ 4,250,000	$ 0